Recent news on Imatinib

Imatinib and Steroids Helpful in Elderly with Acute Lymphoblastic ...  -  May 18, 2007
Cancerpage.com,NEW YORK MAY 18, 2007 (Reuters Health) - Without additional chemotherapy, imatinib along with steroid treatment may induce complete remission and prolong

Dasatinib Effective Against Imatinib-Resistant Leukemia  -  May 2, 2007
Cancerpage.com,NEW YORK MAY 01, 2007 (Reuters Health) - The kinase inhibitor dasatinib induces complete responses in patients with imatinib-resistant or

International Approvals: Focetria, Zetia, Gleevec  -  May 14, 2007
Medscape (subscription)On March 8, Health Canada approved 2 new indications for imatinib mesylate (Gleevec tablets, Novartis Pharmaceuticals Canada, Inc), allowing its use as a

Drug-Resistant Cancer All 'Wrapped Up' By Gleevec  -  May 7, 2007
Medical News Today (press release),In laboratory studies, WBZ-7 was found to be effective against a form of gastrointestinal cancer that has developed a resistance to imatinib, the drug sold

'Wrapping' Gleevec fights drug-resistant cancer  -  May 4, 2007
Cancerfacts.com,It binds with the most effective imatinib-resistant version of KIT. And finally, it binds in a way that ensures that any further version of KIT that becomes

HOT PAPER IN RTK INHIBITORS  -  Apr 25, 2007
Scientist,Imatinib (Gleevec) stunned the world with its high cure rate for chronic myeloid leukemia through the inhibition of tyrosine kinase Bcr-Abl. But,

Unstable Leukemia Stem Cells May Predispose Patients To Drug ...  -  May 6, 2007
Medical News Today (press release),Treatment with imatinib causes clinical remissions in most patients with chronic myeloid leukemia, but relapses are common and the cancer can become

Pfizer Launches New Cancer Treatment In NZ  -  May 3, 2007
Scoop.co.nz,...“Sutent is the first and only agent to be approved in the second line treatment of GIST following treatment with imatinib, and it is good that New

Independent Publication Confirms Growing Therapeutic Challenge of ...  -  May 21, 2007
PharmaLive.com (press release),The T315I Bcr-Abl mutation is associated with the development of resistance to tyrosine kinase inhibitor drugs such as imatinib (Gleevec(R)).

Imatinib Safe After Hematopoietic Cell Transplant in Leukemia Patients  -  Apr 24, 2007
Cancerpage.com,NEW YORK APR 23, 2007 (Reuters Health) - Imatinib prophylaxis at standard dose intensity appears safe following myeloablative hematopoietic cell

Imatinib safe after hematopoietic cell transplant in leukemia patients  -  Apr 23, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Imatinib prophylaxis at standard dose intensity appears safe following myeloablative hematopoietic cell transplantation (HCT) in

HOT PAPER IN RTK INHIBITORS  -  Apr 25, 2007
Scientist,Imatinib (Gleevec) stunned the world with its high cure rate for chronic myeloid leukemia through the inhibition of tyrosine kinase Bcr-Abl. But,

No Interruption in Imatinib Therapy in GI Tumors Recommended  -  Mar 27, 2007
Cancerpage.com,NEW YORK MAR 27, 2007 (Reuters Health) - Imatinib interruption results in rapid progression in most patients with advanced gastrointestinal stromal tumors

Gleevec Decreases Cancer Recurrence For Patients With Primary ...  -  Apr 17, 2007
Medical News Today (press release),Researchers found that approximately 97 per cent of patients in the study who received one year of imatinib after surgery did not have a recurrence of their

INNOVIVE Pharmaceuticals Announces Interim Phase I Data on INNO ...  -  Apr 16, 2007
Genetic Engineering News (press release),1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth

Cancer Drug Trial Halted For Positive Results  -  Apr 16, 2007
eMaxHealth.com,The action was taken by the National Cancer Institute so all eligible patients could start taking imatinib (trade name Gleevec) before the planned release

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 12, 2007
PR Newswire (press release),About Gleevec Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant

Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors  -  Apr 16, 2007
MedIndia,...placebo-controlled clinical trial for patients with primary GIST, showed that patients who received imatinib mesylate (Gleevec) after complete removal

Health Canada approves SPRYCEL(TM), a new treatment for chronic ...  -  Mar 28, 2007
CNW Telbec (Communiqués de presse),...of adults with chronic, accelerated or blast phase CML who fail or are intolerant to prior therapy including imatinib mesylate (marketed as Gleevec(R)).

Gleevec keeps stomach tumor at bay: study  -  Apr 13, 2007
Therapeutics Daily (subscription) (press release),...compared to 83 percent of patients given a placebo. The drug, made by Novartis under the generic name imatinib, was approved five years ago for patients

Gleevec Reduces Stomach Cancer Recurrence -Study  -  Apr 12, 2007
Reuters.uk,The National Institutes of Health team found that 97 per cent of patients in the study who took one year of Gleevec, known generically as imatinib,

Gleevec keeps stomach tumor at bay: study  -  Apr 12, 2007
ReutersThe drug, made by Novartis under the generic name imatinib, was approved five years ago for patients with chronic myeloid leukemia.

UPDATE 1-Gleevec keeps stomach tumor at bay - study  -  Apr 12, 2007
ReutersVX: Quote, Profile, Research) under the generic name imatinib, was approved five years ago for patients with chronic myeloid leukemia.

Killing me Softly…..  -  Mar 30, 2007
Blogger News NetworkThis doctor in china had a patient who was suffering from chronic myeloid leukaemia and needed a drug called Imatinib. The drug was a product of the Swiss

PWRM: Files Utility Patent Application for Resistance Test w ...  -  Apr 10, 2007
Therapeutics Daily (subscription) (press release),The patent application covers a test, a drug target and therapeutic design specifications with the potential to overcome resistance to imatinib mesylate

Novartis case: arguments end  -  Mar 28, 2007
Hindu,...commenced hearing on the statutory appeal of the company against the rejection of its application to patent beta crystalline form of imatinib mesylate,

Novartis case: HC hears appeal  -  Mar 28, 2007
Chennai Online,...commenced hearing a statutory appeal filed by the firm challenging rejection of its application for patenting beta crystalline form of Imatinib Mesylate

Govt defends stance in Novartis patent suit  -  Mar 27, 2007
Daily News & Analysis,...against the rejection of its patent application for beta crystalline form of imatinib mesylate and also challenging section 3 (d) of the Patents Act,

Novartis off to a flyer in 2007 thanks to Diovan and Gleevec  -  Apr 24, 2007
Pharma Times (subscription),...while Gleevec (imatinib) for certain forms of chronic myeloid leukaemia and gastrointestinal stromal tumours increased 16% to $674 million.

Genomics Closes In On Cancer, Mutations, Somatic Or Inherited  -  Apr 16, 2007
BioWorld Online,An example is the use of imatinib and dasatinib, both of which block a hyperactive bcr/abl kinase, to treat chronic myelogenous leukemia.

Novartis licences lead cancer candidate from Antisoma  -  Apr 23, 2007
In-PharmaTechnologist.com,If approved, AS1404 will add to its current arsenal of anticancer treatments: Femara (letrozole), Glivec (imatinib), Sandostatin LAR (octreotide acetate)

Gleevec available to patients in post-surgical GIST study  -  Apr 15, 2007
News-Medical.net,Investigators will begin offering Gleevec (imatinib mesylate) tablets to patients receiving placebo in a major North American clinical trial after an

Positive Results Prompt US National Cancer Institute To Make ...  -  Apr 15, 2007
Medical News Today (press release),Investigators will begin offering Gleevec(R) (imatinib mesylate) tablets to patients receiving placebo in a major North American clinical trial after an

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 13, 2007
PharmaLive.com (press release),Glivec is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Women of childbearing potential should be advised to

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 13, 2007
PharmaLive.com (press release),Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 12, 2007
Earthtimes.orgEAST HANOVER, NJ, April 12 -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North

The Fred Hutchinson Cancer Research Center Adopts the BioMark ...  -  Apr 19, 2007
Genetic Engineering News (press release),...single base pair mutations that develop in the ABl kinase domain in CML cells, which often cause resistance to imatinib mesylate (drug therapy).

Sprycel® Very Active for Treatment of CML in Blast Crisis  -  Apr 19, 2007
Cancer Consultants (press release),Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or – intolerant chronic myeloid leukemia in blast

Positive results for Gleevec in GIST trial  -  Apr 16, 2007
Pharma Times (subscription),Preliminary results from the GIST trial indicate that Novartis' Gleevec (imatinib) can help reduce the risk of stomach cancer recurrence by up to 70%.

OHSU Cancer Institute, 1 Of Largest In GIST Study And Gleevec  -  Apr 15, 2007
Medical News Today (press release),...randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST) showed that patients who received imatinib

Gleevec reduces recurrence in colon cancer  -  Apr 14, 2007
Cancerfacts.com,The pill, sold as Gleevec®(imatinib mesylate) in the US and as Glivec® outside the US, was first approved by the FDA in 2001 for treatment of chronic

Health Highlights: April 13, 2007  -  Apr 13, 2007
Atlanta Journal Constitution (subscription),People who took the drug Gleevec (imatinib mesylate) after having a particular type of gastrointestinal tumor removed were significantly less likely to have

Gleevec keeps stomach tumour at bay  -  Apr 12, 2007
The Age,The drug, made by Novartis under the generic name imatinib, was approved five years ago for patients with chronic myeloid leukaemia.

Gleevac found to dramatically reduce cancer recurrence risk  -  Apr 13, 2007
DailyIndia.com,The efficacy of imatinib mesylate (Gleevec) in preventing a recurrence of gastrointestinal stromal tumour (GIST) was observed during a placebo-controlled

Novartis sells off Gerber business to Nestle for $5.5 billion  -  Apr 13, 2007
Pharma Times (subscription),Meantime, Novartis has published details of a trial of its oncology agent Gleevec/Glivec (imatinib) which show that the drug dramatically reduce the risk of

Gleevac found to dramatically reduce cancer recurrence risk  -  Apr 13, 2007
South Asian Women's Forum,The efficacy of imatinib mesylate (Gleevec) in preventing a recurrence of gastrointestinal stromal tumor (GIST) was observed during a placebo-controlled

National Cancer Institute to Make Gleevec® Available to Patients ...  -  Apr 12, 2007
EndoNurse,EAST HANOVER, NJ -- Investigators will begin offering Gleevec® (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical

Contract win with Novartis Canada  -  Apr 10, 2007
Laboratory Talk,These services involve Novartis's blood level monitoring programme for Gleevec (imatinib mesylate), a medication approved for the treatment of patients with

From the analyst's couch: Drug developer strategies to boost ...  -  Apr 5, 2007
Nature.com (subscription),An example of such a drug is Novartis's Gleevec (imatinib), which generated US$2.2 billion in 2005 following approval for the niche oncology indications

Pfizer's Sutent® Achieves First Line Recommendation For Treatment ...  -  27 Mar 2007
Medical News Today (press release),...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

Novartis: patents provision bereft of guidelines  -  27 Mar 2007
Hindu,The impugned order, turning down Novartis' patent application for beta crystalline form of imatinib mesylate, itself said the product had 30 per cent of

Interruption of Treatment with Gleevec® Not Recommended for GIST  -  Mar 23, 2007
Cancer Consultants (press release),According to an article published in the Journal of Clinical Oncology, interruption in treatment with Gleevec® (imatinib mesylate) is not recommended for

Pharmaceutical Companies: Killing us Slowly  -  Mar 17, 2007
Desicritics.org,This doctor in China had a patient who was suffering from chronic myeloid leukaemia and needed a drug called Imatinib. The drug, also known as Glivec,

Sprycel® Effective after Gleevec® Failure in Patients with CML in ...  -  Mar 14, 2007
Cancer Consultants (press release),Dasatinib induces notable hematologic and cytogenetic responses in charonic-phase chronic myeloid leukemia after failure of imatinib therapy.

Killing me Softly….  -  Mar 14, 2007
Blogger News NetworkThis doctor in china had a patient who was suffering from chronic myeloid leukaemia and needed a drug called Imatinib. The drug was a product of the Swiss

Madras HC to rule on Novartis’ patent case  -  Mar 5, 2007
Economic Times,However, Glivec (generic name: Imatinib mesylate) is not an incremental innovation and is not either a case of evergreening. “Glivec is a new drug,

BioWorld International Correspondent  -  Mar 6, 2007
Therapeutics Daily (subscription) (press release),LONDON - The drug imatinib (Gleevec), which is a highly specific treatment for chronic myelogenous leukemia, also may be able to cause regression of many

Novartis' Gleevec has extra anti-cancer properties - study  -  Mar 2, 2007
Pharma Times (subscription),The German team has discovered evidence that Gleevec (imatinib) switches on a tumour killing pathway, called autophagy, not previously linked to the drug.

Research sheds light on Gleevec mechanism  -  Mar 6, 2007
Cancer Research UK - News & Resources,Gleevec, also known as Glivec and Imatinib, was designed to treat chronic myelogenous leukaemia (CML). It has changed the disease from being a hard-to-treat

Sutent achieves first line EAU approval for kidney cancer  -  Mar 22, 2007
SpiritIndia,...and/or metastatic malignantgastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due toresistance or intolerance.

Sutent achieves first line EAU approval for kidney cancer  -  Mar 22, 2007
HULIQ,...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

Dead Man Walking  -  Mar 9, 2007
Times of India,Chances are you have never heard of the drug, imatinib mesylate, let alone Section 3 (d) of India's Patent Amendment Act of 2005.

'Biomarkers will provide a dynamic approach'  -  Mar 8, 2007
Express Pharma,For exampletrastuzumab (Genentech's Herceptin), imatinib mesylate (Novartis's Gleevec), and cetuximab (ImClone's Erbitux). Besides Biocon, Dr Reddy's Labs

Global Market for Cancer Immunotherapy Worth $37.2 Billion by 2012  -  Mar 7, 2007
PharmaLive.com (press release),The three leading monoclonal antibody cancer treatments-Gleevec (imatinib), Herceptin (trastuzumab) and Rituxan (rituximab)-were multibillion dollar drugs

Golden parachute goes but Vasella backed by shareholders  -  Mar 7, 2007
Pharma Times (subscription),...to sue India over its patent laws, a move brought on by the country's patent office to decline coverage for its cancer drug Glivec/Gleevec (imatinib).

Novartis: court poses queries on core grounds of challenge  -  Mar 5, 2007
Hindu,The writ petitions are against the rejection of an application to patent Novartis' beta crystalline form of imatinib mesylate, by an order dated January 25,

Doctors Without Borders Urges Novartis Shareholders to Join the ...  -  Mar 6, 2007
Doctors Without Borders,The second court case that focuses on the rejection of an Indian patent for Novartis' leukemia drug Glivec/Geevec (Imatinib) will be heard by the same court

Target validation: Determining druggability  -  Mar 2, 2007
Nature.com (subscription),The only outliers were cABL kinase, which is targeted by imatinib (Gleevec; Novartis) and might therefore be explained by a preference for selectivity over

Two-gene Test Correctly Distinguishes GIST from Leiomyosarcoma  -  Feb 28, 2007
Cancer Consultants (press release),Standard treatment for GIST typically includes surgical removal of as much cancer as possible and treatment with the targeted agent Gleevec® (imatinib

Group Purchasing Organization Expands Ability to Participate in ...  -  Feb 28, 2007
Atlantic Information Services, Inc.,He says that cancer therapy Gleevec (imatinib mesylate) is a good example: "They stopped the trial early and put all the participants on the therapy"

SMS Pharmaceuticals ends below issue price  -  Feb 28, 2007
Moneycontrol.com,Sumatriptan Succinate, Sildenafil Citrate, Omeprazole pellets, Ramipril, Almotriptan maleate, Gemcitibine HCl, Imatinib Mesilate and their intermediates

Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis  -  Mar 8, 2007
AJP - Cell Physiology (subscription)Kowanetz M, Kastemar M, Heldin CH, Isaksson A, Nister M, Ostman A. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional